


# The alginate polymer OligoG alters susceptibility of biofilm-embedded non-typeable *Haemophilus influenzae* to ampicillin and ciprofloxacin

Kaja Marienborg <sup>1,2\*</sup>, Ole Herman Ambur<sup>2</sup>, Ole Andreas Løchen Økstad<sup>3</sup> and Dagfinn Skaare<sup>1</sup>

<sup>1</sup>Department of Microbiology, Vestfold Hospital Trust, Tønsberg, Norway; <sup>2</sup>Department of Life Sciences and Health, OsloMet—Oslo Metropolitan University, Oslo, Norway; <sup>3</sup>Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway

\*Corresponding author. E-mail: kajamari@oslomet.no  
 @Karienberg, @OAmbur, @BadBugsLab, @antibiethics

Received 20 December 2022; accepted 29 March 2023

**Objectives:** Treatment of respiratory infections with non-typeable *Haemophilus influenzae* (NTHi) in COPD patients is complicated by biofilm formation, protecting the bacteria against the hosts' immune response and antibiotics. We investigated the antibiofilm and antibacterial effects of the alginate polymer OligoG, alone or combined with ampicillin or ciprofloxacin, on mature NTHi biofilms.

**Materials and methods:** Two unrelated COPD strains with PBP3-mediated  $\beta$ -lactam resistance, with additional TEM-1  $\beta$ -lactamase (Hi-022) or quinolone resistance due to altered GyrA and ParC (Hi-072) were used. Antibiofilm and antibacterial effects were assessed macroscopically, by measurement of biofilm biomass (OD), and by viable cell counts, with determination of minimum biofilm inhibitory concentration (MBIC) and the novel parameter 'minimum concentration for 2 log<sub>10</sub> drop in viable cells in biofilm' (MB2LDC). Drug interactions between OligoG and antibiotics were assessed by comparing expected and observed inhibitory effects (percent inhibition of no-treatment control) of combined treatment.

**Results:** OligoG had dose-dependent biofilm disruptive abilities and a weak inhibitory effect on viable cells. Combination with OligoG (64 g/L) significantly lowered MBIC for ampicillin (both strains) and MB2LDC for ciprofloxacin (Hi-022). For Hi-022, there was significant synergism between OligoG and both antibiotics. For Hi-072, interactions were subtle, but a tendency in direction of antagonism was significant at two concentrations of ciprofloxacin.

**Conclusions:** OligoG shows promise as a potential adjuvant to antibiotics in NTHi infections, but strain-specific factors appear to affect drug interactions and may lead to antagonism. More research is needed to clarify the mechanisms of action of OligoG and interactions with antibiotics.

## Introduction

COPD was the third leading cause of death in humans worldwide in 2020.<sup>1,2</sup> Non-typeable *Haemophilus influenzae* (NTHi), a major Gram-negative pathogen massively contributing to global morbidity, mortality and antibiotic usage, is the most frequent bacterial cause of lower respiratory tract infections in COPD patients and contributes to almost half of infectious exacerbations.<sup>3–5</sup> The worldwide spread of transferable  $\beta$ -lactamases<sup>5,6</sup> forced a switch from ampicillin to  $\beta$ -lactamase-stable  $\beta$ -lactams such as cephalosporins as recommended empirical therapy in severe NTHi infections.<sup>7</sup> Since the year 2000, NTHi strains resistant to cefotaxime and other extended-spectrum cephalosporins

have emerged in several geographical regions and constitute approximately half of the isolates in Japan,<sup>5,6</sup> and dissemination of MDR strains with co-resistance to clinically important non- $\beta$ -lactams such as quinolones, trimethoprim/sulfamethoxazole, tetracyclines and/or macrolides restrict alternative therapeutic options.<sup>6,8,9</sup>

The ability of NTHi to rapidly form biofilm is a central part of pathogenesis in COPD and complicated respiratory tract infections.<sup>2,10–12</sup> The extracellular matrix (ECM) of NTHi biofilm contains large amounts of double-stranded DNA (dsDNA),<sup>13</sup> as well as virulence determinants that facilitate adherence, tissue invasion, and evasion of the host's immune system, such as lipooligosaccharides (LOSs), high molecular weight (HMW) adhesin

protein, Hap protein and IgA proteases.<sup>2,13–17</sup> It has been suggested that intra- and paracellular communities of NTHi may serve as seeds for recurrent and chronic infections, which may explain reports of antimicrobial therapy failure despite *in vitro* susceptibility.<sup>2,15,18</sup> Notably, NTHi biofilm formation is promoted by subinhibitory concentrations of  $\beta$ -lactam antibiotics.<sup>19,20</sup> Whereas biofilm protects NTHi against  $\beta$ -lactams and other antibiotics,<sup>18,20–22</sup> ECM destabilizers (e.g. EDTA and DNase) can restore the efficacy of antibiotics against NTHi in biofilm *in vitro*.<sup>23</sup> Biofilm destabilizers and inhibitors may therefore represent a novel approach to prevention and treatment of respiratory NTHi infections in COPD patients and other vulnerable patient groups.<sup>12</sup>

Alginate oligosaccharides (AOSs) are water-soluble, biologically active substances with demonstrated anti-inflammatory and antimicrobial effects.<sup>12,24–26</sup> One of the most promising AOSs against biofilm infections is ‘OligoG’ (OligoG CF5/20), a low-toxic chelator with antibacterial, antibiofilm and antibiotic-potentiating effects against MDR strains of several Gram-negative species within the family Enterobacteriaceae and the genera *Pseudomonas*, *Acinetobacter* and *Burkholderia*.<sup>12,25</sup> The exact mechanisms of action of OligoG on bacterial biofilm is not known, but current understanding was recently summarized by Hills *et al.*<sup>27</sup> OligoG has orphan drug designation from the EMA and the FDA and is documented safe for human clinical use.<sup>28,29</sup> Several Phase II clinical trials evaluating use of the substance in cystic fibrosis are completed or ongoing (www.ClinicalTrials.gov), and a recent study concluded that inhalation therapy with OligoG may have some effect in reducing *Burkholderia* spp. infection in cystic fibrosis.<sup>28</sup>

We are not aware of previous studies on the effects of OligoG or other AOSs on *H. influenzae*, and AOSs have to our knowledge not been evaluated for clinical use in COPD patients. This study aimed to investigate the *in vitro* antibiofilm and antibacterial effects of OligoG on mature NTHi biofilm, alone and in the presence of antibiotics (ampicillin or ciprofloxacin), with particular emphasis on drug interactions (synergism or antagonism).

## Materials and methods

### OligoG

OligoG (OligoG CF-5/20) was obtained from the manufacturer (AlgiPharma AS, Sandvika, Norway). The active ingredient, with the formula  $(\text{NaC}_6\text{H}_7\text{O}_6)_n$  is derived from the marine brown alga *Laminaria hyperborea* and has an average polymeric length of 18, a molecular weight of 3200 g/mol, an alpha-L-guluronic acid content of 85%, and a  $\beta$ -D-mannuronic acid content of 15%.<sup>24–26,30</sup> For use in this study, spray dry powder was dissolved in sterile brain heart infusion (BHI) broth using magnetic rotation to obtain a homogenous 5% stock solution, which was diluted in sterile BHI to 2%, 1% and 0.5% (corresponding to 64, 32 and 16 g/L, respectively) for use in the experiments.

### Bacterial strains

Strains Hi-022 and Hi-072 were obtained from a collection of well-characterized, anonymized clinical isolates of *H. influenzae* from a nationwide molecular epidemiologic study (D. Skaare, unpublished data). The two strains were selected based on clinical data (sampled from COPD patients), different phylogenetic lineages and phenotypically expressed resistance mechanisms towards quinolones<sup>31</sup> and/or  $\beta$ -lactams (Table 1). Upon inclusion, the strains were characterized by antimicrobial

susceptibility testing, including determination of MIC according to recommendations from EUCAST, and by WGS (Ion S5 XL, Thermo Fisher Scientific) with subsequent bioinformatic analyses (detailed in Table 1).

### Biofilm formation and antimicrobial challenge assay

A biofilm assay suitable for assessment of antibacterial and antibiofilm effects was established based on methods described in previous studies of NTHi biofilms, with some modifications.<sup>10,23,32–36</sup> Frozen cultures (one pellet) were used to inoculate 5 mL of preheated BHI broth (Oxoid, Thermo Fisher Scientific) supplemented with 2 mg/L NAD (BioNor Laboratories AS) and 10 mg/L haemin (Sigma-Aldrich) (sBHI) and incubated at 35°C in 5% CO<sub>2</sub> for 24 h.<sup>19,23,32,33,36</sup> Cultures were diluted 1:10 in 5 mL of fresh sBHI to 1 McFarland (approximately  $3 \times 10^8$  cfu/mL) and incubated statically for approximately 2 h to reach an OD at 600 nm (OD<sub>600</sub>) of 0.3 by spectrophotometry (GeneQuant 1300, GE Healthcare). For biofilm formation, 125  $\mu$ L of culture and 100  $\mu$ L of preheated sBHI were added to each well of a round-bottom, polystyrene, 96-well microtitre plate (Greiner Bio-One GmbH). The plate was incubated statically for 40 h at 35°C in 5% CO<sub>2</sub>, with careful replacement of broth with fresh preheated sBHI broth after 16–18 h.<sup>32,35</sup> Finally, the biofilms were gently washed twice in sterile water to remove planktonic cells.<sup>23,37</sup>

Mature biofilms were treated (24 h) with OligoG at concentrations of 16, 32 and 64 g/L, and with ampicillin or ciprofloxacin at concentrations corresponding to three to four 2-fold dilutions centred around the respective MICs. In addition, mature biofilms were challenged with OligoG (fixed concentration of 64 g/L) in combination with ampicillin or ciprofloxacin, using the same antibiotic concentrations as described above. The OligoG concentrations were chosen based on an *in vivo* animal study showing a kill effect on *Pseudomonas aeruginosa* in mouse lungs of 1–2 log<sub>10</sub> at concentrations 0.5%–3%.<sup>38</sup>

After treatment, biomasses of each biofilm were determined spectrophotometrically (OD<sub>600</sub>) by thoroughly scraping and pipetting, followed by vigorous resuspension in 5 mL of sBHI, as described by Dawe *et al.*<sup>32</sup> (with modifications). For quantification of viable cells, the suspensions were diluted to 10<sup>-8</sup> and seeded quantitatively on Colombia agar plates (BBL Colombia agar, Becton Dickinson) with 15 mg/L NAD and 15 mg/L haemin.<sup>8</sup> The agar plates were incubated at 35°C in 5% CO<sub>2</sub> for 48 h, with subsequent determination of cfu/mL by colony counts.

In each challenge experiment (OligoG, ampicillin, ciprofloxacin, OligoG/ampicillin and OligoG/ciprofloxacin), two sets of biofilm triplicates were included as pretreatment control and no-treatment control, with quantification of biofilm biomass and viable cells at 40 h (before treatment) and 64 h, respectively.<sup>32,39</sup>

The five challenge experiments were performed using different biological replicates (on separate days), each with three technical replicates. Fifteen replicates of control biofilms (five biological and three technical) were used to assess the relative contribution of biological and technical factors to variability in viable cell counts.

### Assessment of antibiofilm and antibacterial effects of OligoG and/or antibiotics on mature biofilm

Antibiofilm effects were assessed by inspection for macroscopically visible changes in appearance and changes in biofilm biomass by measurement of OD<sub>600</sub> after exposure to OligoG and/or antibiotics, compared with no treatment.

Antibacterial effects were assessed by determination of minimum biofilm inhibitory concentration (MBIC), the novel parameter ‘minimum concentration for 2 log<sub>10</sub> drop in viable cells in biofilm’ (designated ‘MB2LDC’) and biofilm bactericidal concentration (BBC). MBIC was defined as the concentration of tested substance resulting in no increase in viable biofilm cells, while MB2LDC (this study) and BBC were defined as the concentrations resulting in  $\geq 2$  log<sub>10</sub> and  $\geq 3$  log<sub>10</sub> drop in viable biofilm cells, respectively, compared with no treatment.<sup>40</sup> The rationale for the novel

**Table 1.** Characteristics of the *H. influenzae* strains used in the experiments

Strain	Source	Serotype <sup>a</sup>	ST <sup>b</sup>	Resistance mechanisms <sup>c</sup>		MIC (mg/L) and susceptibility category <sup>f</sup>		
				β-Lactams	Quinolones	Ampicillin	Ampicillin/ sulbactam	Ciprofloxacin
Hi-022	Sputum from patient with COPD	Non-typeable	ST836	TEM-1 β-lactamase Group III(+) high-rPBP3 <sup>d</sup>	None	>16 (R)	8 (R)	≤0.06 (S)
Hi-072	Sputum from patient with COPD	Non-typeable	ST1	Group III(+) high-rPBP3 <sup>d</sup>	Altered GyrA and ParC <sup>e</sup>	2 (R)	2 (R)	1 (R)

<sup>a</sup>Using hicap v.1.0.3 (<https://github.com/scwatts/hicap>).

<sup>b</sup>By MLST (<https://pubmlst.org/organisms/haemophilus-influenzae>).

<sup>c</sup>Transferable genes were detected using ResFinder v.4.1 (<https://cge.food.dtu.dk/services/ResFinder>); alterations in chromosomal genes were detected by multiple sequence alignment of translated genes, with *H. influenzae* Rd KW20 (GCA\_000027305) as reference.

<sup>d</sup>Characterized by the S385T, L389F and N526K substitutions in the transpeptidase region of PBP3.<sup>6</sup>

<sup>e</sup>Substitutions in the QRDRs of GyrA (S84L) and ParC (S84I) present.<sup>31</sup>

<sup>f</sup>MICs were determined by broth microdilution according to recommendations from EUCAST ([https://www.eucast.org/ast\\_of\\_bacteria](https://www.eucast.org/ast_of_bacteria)), using custom MIC panels (Sensititre NONAG7, Thermo Fisher Scientific), and interpreted (S, susceptible; R, resistant) according to the most recent version of the EUCAST breakpoint table (version 13.0).

parameter MB2LDC is that a 2 log<sub>10</sub> drop is a widely used pharmacodynamic parameter in time-kill studies and also corresponds to the clinical effect of amoxicillin and ciprofloxacin.<sup>41–43</sup> For combined treatment with OligoG (64 g/L) and antibiotics, MBIC, MB2LDC and BBC values were expressed as the antibiotic concentration. For comparison of antibacterial effects of individual antibiotic treatment and combined antibiotic/OligoG treatment, we calculated ratios of MBIC, MB2LDC and BBC by antibiotic treatment to the same parameters by combined treatment. Ratios of ≥8 were considered significant, corresponding to the definition of synergy by determination of MIC:MIC ratio (3 or more 2-fold dilutions).<sup>44</sup>

For a more sophisticated assessment of interactions between OligoG and antibiotic (synergism or antagonism), we compared expected and observed inhibitory effects of combined treatment on viable cells, expressed as percent change in viable cells (log<sub>10</sub> cfu/mL) compared with no-treatment control. The Bliss independence approach was used to calculate expected inhibitory effects at each antibiotic concentration, using the formula  $I_{1,2} = I_1 + I_2 - I_1I_2$  where  $I_1$  and  $I_2$  are the inhibitory effects by individual treatments with drug 1 (OligoG) and 2 (antibiotic), respectively,  $I_{1,2}$  represents the expected inhibitory effect of combined treatment, and  $I_1I_2$  represents the product of  $I_1$  and  $I_2$ .<sup>45,46</sup> Mean inhibitory effects by individual treatments ( $I_1$  and  $I_2$ ) (three technical replicates) were used as input in the formula to calculate the expected inhibitory effect of combined treatment ( $I_{1,2}$ ). The expected effect was compared with the observed inhibitory effect of combined treatment, calculated separately for each of the three technical replicates, with subsequent calculation of means and determination of 95% CI. Significant synergism was defined as 'observed effect (lower 95% CI) > expected effect' while significant antagonism was defined as 'observed effect (upper 95% CI) < expected effect'.<sup>46</sup>

### Statistical analysis

Excel (Microsoft Corporation, Redmond, WA, USA) was used to organize, analyse and visualize the data. Assessment of antibiofilm and antibacterial effects was based on calculated means (OD<sub>600</sub> and mean log<sub>10</sub> cfu/mL, respectively) from triplicate testing. The relative contribution of biological and technical factors to variability in viable cell counts (log<sub>10</sub> cfu/mL) in the biofilm assay was assessed by comparing mean coefficients of variation (CV) for technical replicates with CV across five biological replicates

of each strain. Normal distribution was assessed using Q-Q Plot in SPSS Statistics 28 (IBM, Armonk, NY, USA). Assessing significance of drug interaction was done by comparing mean expected inhibitory effect of combined treatment with mean observed inhibitory effect and 95% CI (described in detail above). CIs were determined assuming Student's *t*-distribution to account for the low sample size (triplicates) and the lack of biological replicates in the challenge experiments.

### Ethics

All personal data used in this study were anonymized. The study strains were recruited from a study (D. Skaare, unpublished data) approved by the Regional Committees for Medical and Health Research Ethics in Norway (reference number 2018/1558) and the Norwegian Data Protection Services (reference number 232381).

### Data availability

Genomic sequences for strains Hi-022 and Hi-072 are deposited at <https://www.ebi.ac.uk/ena> under BioProject PRJEB49398, accession numbers GCA\_923256855 and GCA\_923258785, respectively.


## Results

### Biofilm assay variability

For both strains, viable cell counts (log<sub>10</sub> cfu/mL) from the 15 replicates (5 biological and 3 technical) of untreated biofilms (no-treatment control) were normally distributed (data not shown). Variability between technical replicates (mean CV 3.6% for both strains) was comparable to the variability between biological replicates (CV 4.4% and 3.0% for Hi-022 and Hi-072, respectively).

### Antibiofilm effects of individual treatment of biofilms with OligoG, ampicillin or ciprofloxacin

OligoG was found to have a concentration-dependent antibiofilm effect on mature biofilm from both strains, assessed by macroscopic inspection (not shown). Compared with the no-treatment



**Figure 1.** Antibacterial and antibiofilm effects of individual treatment of mature biofilms with OligoG, ampicillin or ciprofloxacin. Antibacterial effect was measured as change in viable cells ( $\log_{10}$  cfu/mL, left axis), while antibiofilm effect was measured as change in biofilm biomass ( $OD_{600}$ , right axis). All values are means of three technical replicates. NTC, no-treatment control. Vertical lines indicate MBIC (dashed), MB2LDC (dotted/dashed) and BBC by individual treatment (summarized in Table 2; see text for definitions). Vertical axis scales are harmonized between plots for easier comparison.

control, treated biofilms were more dispersed and granulated, and less sheetlike. In contrast, there were no noticeable macroscopic differences between no treatment and treatment with ampicillin or ciprofloxacin. There were no clear dose-dependent associations between exposure to OligoG or antibiotics and changes in biofilm biomass at the tested concentrations (Figure 1, dotted lines).

### Antibacterial effects of individual treatment of biofilms with OligoG, ampicillin or ciprofloxacin

Antibacterial effects of individual treatments of mature biofilms with OligoG or antibiotics (expressed as changes in  $\log_{10}$  cfu/mL) are shown in Figure 1. The corresponding MBIC, MB2LDC and BBC values (indicated by vertical lines) are summarized in Table 2. There was a weak concentration-dependent antibacterial effect of OligoG on both strains, with MBIC values of  $\leq 16$  g/L (Hi-022) and 32 g/L (Hi-072). At the concentration used for combined treatment (64 g/L), the inhibitory effects of OligoG on the two strains (calculated as percent inhibition of viable cells compared with no-treatment control) were 8.9% and 6.5%, respectively (not shown). The tested concentration ranges did not allow determination of exact antibiotic MBICs for strain Hi-022. For strain Hi-072, the ampicillin MBIC was one 2-fold dilution above MIC, whereas the


ciprofloxacin MBIC was identical to the corresponding MIC value (Figure 1). All MB2LDC and BBC values exceeded the tested concentration ranges, i.e. a 2  $\log_{10}$  drop in cfu/mL compared with the no-treatment control was not achieved for any of the tested strain/drug combinations.

### Antibiofilm effects of combined treatment of biofilms with OligoG and ampicillin or ciprofloxacin

Biofilms treated with combinations of OligoG and antibiotics showed macroscopic changes similar to those observed after individual treatment with OligoG alone (not shown). Compared with no-treatment control, combined treatment resulted in consistently decreased biofilm biomass (as measured by  $OD_{600}$ ) for all strain/drug combinations (Figure 2, dotted lines).

### Antibacterial effects of combined treatment of biofilms with OligoG and ampicillin or ciprofloxacin

Antibacterial effects of combined treatment of mature biofilms with OligoG and antibiotics (expressed as changes in  $\log_{10}$  cfu/mL) are shown in Figure 2. The corresponding MBIC, MB2LDC and BBC values (indicated by vertical lines) are summarized in Table 2. For both strains, all MBICs were equal to or lower than the lowest antibiotic concentration tested. Conversely, all MB2LDC and BBC values




**Figure 2.** Antibacterial and antibiofilm effects of combined treatment of mature biofilms with antibiotic (ampicillin or ciprofloxacin) in combination with 64 g/L OligoG. Antibacterial effect was measured as change in viable cells ( $\log_{10}$  cfu/mL, left axis), while antibiofilm effect was measured as change in biofilm biomass ( $OD_{600}$ , right axis). All values are means of three technical replicates. NTC, no-treatment control. Vertical lines indicate MBIC (dashed), MB2LDC (dotted/dashed) and BBC by combined treatment (summarized in Table 2; see text for definitions). Vertical axis scales are harmonized between plots for easier comparison.

exceeded the tested concentration ranges, except for strain Hi-022 and OligoG/ciprofloxacin, where a 2  $\log_{10}$  drop (MB2LDC) was obtained with the lowest tested concentration of ciprofloxacin (0.03 mg/L), and a 3  $\log_{10}$  drop (BBC) was obtained with 0.5 mg/L antibiotic. For the  $\beta$ -lactamase-positive strain Hi-022, there was a marked drop in viable cells at the ampicillin concentration corresponding to MIC for ampicillin/sulbactam (8 mg/L) (Figure 2). Compared with individual antibiotic treatment, combined treatment with antibiotic and OligoG gave significantly lower MBIC for ampicillin (both strains) and MB2LDC for ciprofloxacin (Hi-022) (Table 2). For the  $\beta$ -lactamase-positive strain Hi-022,

there was a marked drop in viable cells at the ampicillin concentration corresponding to MIC for ampicillin/sulbactam (8 mg/L) (Figure 2).

### Drug interactions between OligoG and antibiotics

Expected and observed inhibitory effects of combined treatment of mature biofilms with OligoG and antibiotics (expressed as percent inhibition of no-treatment control) are shown in Figure 3. For strain Hi-022, we found significant synergistic effect between OligoG and ampicillin at ampicillin concentrations in the range 8–256 mg/L, and



**Figure 3.** Expected and observed inhibitory effects of combined treatment of mature biofilms with antibiotic (ampicillin or ciprofloxacin) and 64 g/L OligoG. Inhibitory effects are expressed as percent change in viable cells ( $\log_{10}$  cfu/mL) compared with no-treatment control. Expected effects (dashed lines) were calculated using the Bliss independence approach (see text for formula) with mean inhibitory effects by individual treatments (three technical replicates) as input. Observed inhibitory effects (full lines) were calculated separately for each of the three technical replicates, with subsequent calculation of means and determination of 95% CI (assuming Student's *t*-distribution to account for low sample size). Significant synergism was defined as 'observed effect (lower 95% CI) > expected effect' while significant antagonism was defined as 'observed effect (upper 95% CI) < expected effect'. Significant synergism or antagonism is indicated by asterisks above or below 95% CI, respectively. Vertical lines indicate MBIC (dashed), MB2LDC (dotted/dashed) and BBC by combined treatment (Table 2). Axis scales are harmonized for easier comparison.

between OligoG and ciprofloxacin at ciprofloxacin concentrations in the range 0.125–1 mg/L. In contrast, there was generally little difference between the expected and observed inhibitory effects of combined treatment for strain Hi-072. For this strain, the observed effect of OligoG combined with ciprofloxacin tended to be weaker than the expected effect (i.e. in the direction of antagonism) at ciprofloxacin concentrations in the range 1–16 mg/L; however, the difference was significant only at two concentrations (1 and 16 mg/L).

## Discussion

In this *in vitro* study, we investigated the potential of the AOS OligoG as a biofilm inhibitor for clinical use in combination with antibiotics in NTHi infections. OligoG has shown promise as adjuvant to several antibiotics for treatment of respiratory biofilm infections caused by a wide range of Gram-negative bacteria.<sup>12,30</sup> To the best of our knowledge, the present study is the first investigation of the effects of OligoG on *H. influenzae*, the first study

**Table 2.** Antibacterial activity of individual or combined treatment with OligoG, ampicillin and/or ciprofloxacin on *H. influenzae* in mature biofilms

Strain	Parameter	OligoG (g/L)	Ampicillin (mg/L)			Ciprofloxacin (mg/L)		
			alone or combined with OligoG (64 g/L)	Individual treatment	Combined treatment	Ratio <sup>b</sup>	alone or combined with OligoG (64 g/L)	Individual treatment
Hi-022	MBIC	≤16	>500 <sup>a</sup>	≤4	≥125*	≤0.03	≤0.03	Indeterminate
	MB2LDC	>64	>500 <sup>a</sup>	>500	Indeterminate	>1	≤0.03	≥32*
	BBC	>64	>500 <sup>a</sup>	>500	Indeterminate	>1	0.5	≥2
Hi-072	MBIC	32	4	≤0.5	≥8*	1	≤0.5	≥1
	MB2LDC	>64	>64	>64	Indeterminate	>16	>16	Indeterminate
	BBC	>64	>64	>64	Indeterminate	>16	>16	Indeterminate

Asterisk indicates significant decrease (ratio ≥8).<sup>44</sup>

<sup>a</sup>For technical reasons, the highest concentration tested was 500 mg/L (i.e. deviating from the standardized 2-fold scale)

<sup>b</sup>Ratio of MBIC, MB2LDC or BBC by individual treatment to the same parameter by combined treatment.

exploring drug interactions between OligoG and ampicillin, and only the second study performed independently of the manufacturer (the first being Hills *et al.*<sup>27</sup>). Using mature NTHi biofilms from two unrelated COPD strains, we found that OligoG inhibited growth of bacteria in biofilm at concentrations ≤16 g/L and 32 g/L (MBIC). We are not aware of previous studies with determination of OligoG MBICs, but Khan *et al.*<sup>30</sup> reported that 64 g/L (2%) OligoG had no inhibitory effect on an *Escherichia coli* strain in liquid culture, and variable inhibitory effect on *Klebsiella pneumoniae* strains. Although we did not investigate the activity of OligoG against planktonic bacteria in the present study, these observations suggest that the intrinsic antibacterial activity of OligoG, similar to other antimicrobial agents, may vary between strains and species.

The basis for our selection of antibiotics was that ampicillin is the preferred drug for parenteral treatment of infections with susceptible strains of *H. influenzae*, while ciprofloxacin is an attractive option for oral treatment of infections caused by ampicillin-resistant strains. Moreover, some studies have suggested that quinolones are more effective than aminopenicillins against NTHi in mature biofilm.<sup>19–21</sup> In an *in vitro* study on NTHi in biofilm, elimination rates of ciprofloxacin and amoxicillin/clavulanic acid were 68% and 3.6%, respectively.<sup>21</sup> In contrast, another study found no significant difference between the abilities of ampicillin and ciprofloxacin to kill NTHi in biofilm *in vitro*.<sup>23</sup>

A recent report illustrated that susceptibility to ciprofloxacin as determined by conventional antimicrobial susceptibility testing is no guarantee for therapeutic success in complicated respiratory NTHi infections.<sup>9</sup> Susceptibility categorization of bacteria based on planktonic bacteria (e.g. MIC) can not be used to predict therapeutic outcome in biofilm infections, and a standardized methodology for susceptibility testing of bacteria in biofilm that correlates to therapeutic outcome is lacking.<sup>40,47</sup> MBIC is the biofilm-specific pharmacodynamic parameter that corresponds best to MIC. Although MBIC and MIC are based on different methodologies and therefore not directly comparable, it is generally assumed that the antibiotic concentration representing MBIC is 4- to 1000-fold higher than the corresponding MIC, depending on bug/drug combination.<sup>40,48</sup> Interestingly, for strain Hi-072, antibiotic MBICs were similar to (ciprofloxacin) or only one

dilution higher (ampicillin) than the corresponding MICs. Our results are in line with previous investigations of the activities of ampicillin and quinolones against NTHi in biofilm,<sup>19,49</sup> suggesting that NTHi biofilms may have different properties in terms of antibiotic penetration compared with other species.

MBIC and BBC are often used to express antibiotic effect on bacteria in biofilm.<sup>40</sup> Here, the additional novel parameter MB2LDC is introduced as a biofilm-specific parallel to the antibacterial effect measure (2 log<sub>10</sub> drop) corresponding to clinical effect in time-kill studies.<sup>39–43</sup> We found that MB2LDC for ciprofloxacin/OligoG and strain Hi-022 was significantly lower than MB2LDC for ciprofloxacin alone, and lower than the clinical MIC breakpoint recommended by EUCAST (susceptible ≤ 0.06 mg/L). Similarly, ampicillin/OligoG MBICs were significantly lower than ampicillin MBICs for both strains, and in the case of strain Hi-072 lower than the clinical MIC breakpoint (susceptible ≤ 1 mg/L). These observations suggest that combination with OligoG could increase the probability of therapeutic effect of ampicillin and ciprofloxacin in NTHi biofilm infections.

Current and emerging pharmaceutical strategies for combating respiratory biofilm infections, including combination of antibiotics and non-antibiotic adjuvants was recently reviewed by Zhang *et al.*<sup>12</sup> The authors underlined that the exact mechanism of the antibiofilm effects of OligoG is unclear, but classified OligoG among extracellular matrix-interfering agents with the ability to potentiate a wide range of antibiotics.<sup>24–26,30</sup> While studies have shown that OligoG has intrinsic antimicrobial activity<sup>24</sup> and/or that antibiotics are more effective combined with OligoG than alone,<sup>24–26,30</sup> we have not been able to identify studies describing interactions between OligoG and antibiotics in terms of assessing true synergy, i.e. whether the combined inhibitory effect exceeds the added effect of the two drugs. In the present study, we used the approach described by Prichard *et al.*, based on comparison of expected and observed combined inhibitory effects, with calculation of expected effect based on the Bliss independence approach.<sup>46</sup> Unlike the more widely used FIC index (FICI), this approach allows assessment of drug interactions without exact MBIC values for OligoG and all antibiotic/strain combinations.<sup>50</sup> Our results suggest that OligoG may act synergistically with both ampicillin and ciprofloxacin

against NTHi, but that the effect varies between strains and in some cases may even be antagonistic. Interestingly, for the  $\beta$ -lactamase-producing strain Hi-022, ampicillin/OligoG MBIC was lower than MIC for ampicillin/sulbactam. Further research should clarify whether this reflects a possible interaction between OligoG and  $\beta$ -lactamase activity. Furthermore, synergy was most evident for the strain with the lowest OligoG MBIC, suggesting that lack of synergy may be linked to unidentified, strain-specific OligoG resistance mechanisms. Nevertheless, the synergism observed for strain Hi-022 is to our knowledge the first report of demonstrated synergy between a biofilm inhibitor and antibiotics in *H. influenzae*, or between OligoG and antibiotics overall. In contrast, a previous investigation (using the FICI approach) found only additive effects between EDTA and ampicillin or ciprofloxacin against NTHi in biofilm.<sup>23</sup>

This study has several limitations. First, the five challenge experiments were performed with different, single biological replicates. Consequently, whether biological variation between different versions of the strains may have affected the results remains largely unexplored, although assessment of variability among untreated control biofilms suggested that technical factors had a larger impact than biological factors. Second, due to the small sample size in each experiment (three technical replicates), it was not possible to assess whether data were normally distributed. To compensate for these uncertainties, we chose a conservative statistical approach by assuming Student's *t*-distribution in our calculations of 95% CI. This may, on the other hand, have led to underreporting of significant drug interactions. Nevertheless, the experimental design does not allow firm conclusions and the results should be interpreted with caution. Furthermore, the number of strains and drug concentration ranges were limited, and broader investigations (additional strains and antibiotics, combined with variable OligoG concentrations) should be undertaken to further explore clinically relevant drug interactions. In conclusion, OligoG shows promise as a potential adjuvant to ampicillin and ciprofloxacin in NTHi infections, but the usefulness in COPD patients must be validated in clinical studies. Importantly, strain-specific factors appear to affect drug interactions and may lead to significant antagonism. More research is therefore needed to clarify the mechanisms of action of OligoG and molecular mechanisms affecting interactions with antibiotics.

## Acknowledgements

We thank Hedda R ath, Gunnhild Sommernes, Helene Johannessen Wefring, Mette Lundstr om Dahl, Gl er Gl ersen and Maren Nordsveen Davis for technical assistance, and the Department of Microbiology, Vestfold Hospital Trust, for access to the necessary infrastructure to perform the experimental procedures. We are also grateful to AlgiPharma AS for selling us OligoG CF-5/20 for use in the study.

## Funding

This work was supported by grants from the Helse S r- st RHF, Norway (grant number 2020107), the regional research network 'Turning the Tide of Antibiotic Resistance' (des-2020), the Norwegian Surveillance System for Antimicrobial Drug Resistance (NORM) (19\_07),

Sykehuset i Vestfold (04.02.2021) and Storbyuniversitetet (OsloMet) (Forskerlinjen-2021).

## Transparency declarations

All authors has stated they have none to declare. And AlgiPharma AS was not involved in funding, designing, or performing the study, nor in the analysis, interpretation, or publication of data.

## References

- 1 WHO. Chronic obstructive pulmonary disease (COPD). [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)).
- 2 Weeks JR, Staples KJ, Spalluto CM et al. The role of non-typeable *Haemophilus influenzae* biofilms in chronic obstructive pulmonary disease. *Front Cell Infect Microbiol* 2021; **11**: 720742. <https://doi.org/10.3389/fcimb.2021.720742>
- 3 Su YC, Jalalvand F, Thegerstr m J et al. The interplay between immune response and bacterial infection in COPD: focus upon non-typeable *Haemophilus influenzae*. *Front Immunol* 2018; **9**: 2530. <https://doi.org/10.3389/fimmu.2018.02530>
- 4 Ahearn CP, Gallo MC, Murphy TF. Insights on persistent airway infection by non-typeable *Haemophilus influenzae* in chronic obstructive pulmonary disease. *Pathog Dis* 2017; **75**: ftx042. <https://doi.org/10.1093/femspd/ftx042>
- 5 Van Eldere J, Slack MP, Ladhani S et al. Non-typeable *Haemophilus influenzae*, an under-recognised pathogen. *Lancet Infect Dis* 2014; **14**: 1281–92. [https://doi.org/10.1016/S1473-3099\(14\)70734-0](https://doi.org/10.1016/S1473-3099(14)70734-0)
- 6 Skaare D, Anthonisen IL, Kahlmeter G et al. Emergence of clonally related multidrug resistant *Haemophilus influenzae* with penicillin-binding protein 3-mediated resistance to extended-spectrum cephalosporins, Norway, 2006 to 2013. *Euro Surveill* 2014; **19**: 20986. <https://doi.org/10.2807/1560-7917.ES2014.19.49.20986>
- 7 Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in *Haemophilus influenzae*. *Clin Microbiol Rev* 2007; **20**: 368–89. <https://doi.org/10.1128/CMR.00040-06>
- 8 Johannessen H, Anthonisen IL, Zecic N et al. Characterization and fitness cost of Tn7100, a novel integrative and conjugative element conferring multidrug resistance in *Haemophilus influenzae*. *Front Microbiol* 2022; **13**: 945411. <https://doi.org/10.3389/fmicb.2022.945411>
- 9 Lindemann PC, Mylvaganam H, Oppegaard O et al. Case report: whole-genome sequencing of serially collected *Haemophilus influenzae* from a patient with common variable immunodeficiency reveals within-host evolution of resistance to trimethoprim-sulfamethoxazole and azithromycin after prolonged treatment with these antibiotics. *Front Cell Infect Microbiol* 2022; **12**: 896823. <https://doi.org/10.3389/fcimb.2022.896823>
- 10 Baddal B. Characterization of biofilm formation and induction of apoptotic DNA fragmentation by nontypeable *Haemophilus influenzae* on polarized human airway epithelial cells. *Microb Pathog* 2020; **141**: 103985. <https://doi.org/10.1016/j.micpath.2020.103985>
- 11 Swords WE. Nontypeable *Haemophilus influenzae* biofilms: role in chronic airway infections. *Front Cell Infect Microbiol* 2012; **2**: 97. <https://doi.org/10.3389/fcimb.2012.00097>
- 12 Zhang L, Bera H, Wang H et al. Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections. *Int J Pharm* 2022; **616**: 121507. <https://doi.org/10.1016/j.ijpharm.2022.121507>
- 13 Jurcisek JA, Bakaletz LO. Biofilms formed by nontypeable *Haemophilus influenzae* in vivo contain both double-stranded DNA and



- type IV pilin protein. *J Bacteriol* 2007; **189**: 3868–75. <https://doi.org/10.1128/JB.01935-06>
- 14** Webster P, Wu S, Gomez G 3rd et al. Distribution of bacterial proteins in biofilms formed by non-typeable *Haemophilus influenzae*. *J Histochem Cytochem* 2006; **54**: 829–42. <https://doi.org/10.1369/jhc.6A6922.2006>
- 15** Sriram KB, Cox AJ, Clancy RL et al. Nontypeable *Haemophilus influenzae* and chronic obstructive pulmonary disease: a review for clinicians. *Crit Rev Microbiol* 2018; **44**: 125–42. <https://doi.org/10.1080/1040841X.2017.1329274>
- 16** Atack JM, Day CJ, Poole J et al. The HMW2 adhesin of non-typeable *Haemophilus influenzae* is a human-adapted lectin that mediates high-affinity binding to 2-6 linked N-acetylneuraminic acid glycans. *Biochem Biophys Res Commun* 2018; **503**: 1103–7. <https://doi.org/10.1016/j.bbrc.2018.06.126>
- 17** Wu S, Baum MM, Kerwin J et al. Biofilm-specific extracellular matrix proteins of nontypeable *Haemophilus influenzae*. *Pathog Dis* 2014; **72**: 143–60.
- 18** van Schilfgaarde M, Eijk P, Regelink A et al. *Haemophilus influenzae* localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity. *Microb Pathog* 1999; **26**: 249–62. <https://doi.org/10.1006/mpat.1998.0269>
- 19** Kaji C, Watanabe K, Apicella MA et al. Antimicrobial effect of fluoroquinolones for the eradication of nontypeable *Haemophilus influenzae* isolates within biofilms. *Tohoku J Exp Med* 2008; **214**: 121–8. <https://doi.org/10.1620/tjem.214.121>
- 20** Umar NK, Kono M, Sakatani H et al. Respiratory quinolones can eradicate amoxicillin-induced mature biofilms and nontypeable *Haemophilus influenzae* in biofilms. *J Infect Chemother* 2022; **28**: 1595–604. <https://doi.org/10.1016/j.jiac.2022.07.019>
- 21** Slinger R, Chan F, Ferris W et al. Multiple combination antibiotic susceptibility testing of nontypeable *Haemophilus influenzae* biofilms. *Diagn Microbiol Infect Dis* 2006; **56**: 247–53. <https://doi.org/10.1016/j.diagmicrobio.2006.04.012>
- 22** Starner TD, Zhang N, Kim G et al. *Haemophilus influenzae* forms biofilms on airway epithelia: implications in cystic fibrosis. *Am J Respir Crit Care Med* 2006; **174**: 213–20. <https://doi.org/10.1164/rccm.200509-1459OC>
- 23** Cavaliere R, Ball JL, Turnbull L et al. The biofilm matrix destabilizers, EDTA and DNaseI, enhance the susceptibility of nontypeable *Haemophilus influenzae* biofilms to treatment with ampicillin and ciprofloxacin. *Microbiologyopen* 2014; **3**: 557–67. <https://doi.org/10.1002/mbo3.187>
- 24** Pritchard MF, Powell LC, Jack AA et al. A low-molecular-weight alginate oligosaccharide disrupts pseudomonal microcolony formation and enhances antibiotic effectiveness. *Antimicrob Agents Chemother* 2017; **61**: e00762–17. <https://doi.org/10.1128/AAC.00762-17>
- 25** Hengzhuang W, Song Z, Ciofu O et al. OligoG CF-5/20 disruption of mucoid *Pseudomonas aeruginosa* biofilm in a murine lung infection model. *Antimicrob Agents Chemother* 2016; **60**: 2620–6. <https://doi.org/10.1128/AAC.01721-15>
- 26** Powell LC, Pritchard MF, Ferguson EL et al. Targeted disruption of the extracellular polymeric network of *Pseudomonas aeruginosa* biofilms by alginate oligosaccharides. *NPJ Biofilms Microbiomes* 2018; **4**: 13. <https://doi.org/10.1038/s41522-018-0056-3>
- 27** Hills OJ, Yong CW, Scott AJ et al. Polyguluronate simulations shed light onto the therapeutic action of OligoG CF-5/20. *Bioorg Med Chem* 2022; **72**: 116945. <https://doi.org/10.1016/j.bmc.2022.116945>
- 28** Fischer R, Schwarz C, Weiser R et al. Evaluating the alginate oligosaccharide (OligoG) as a therapy for *Burkholderia cepacia* complex cystic fibrosis lung infection. *J Cyst Fibros* 2022; **21**: 821–9. <https://doi.org/10.1016/j.jcf.2022.01.003>
- 29** van Koningsbruggen-Rietschel S, Davies JC, Pressler T et al. Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study. *ERJ Open Res* 2020; **6**: 00132–2020. <https://doi.org/10.1183/23120541.00132-2020>
- 30** Khan S, Tondervik A, Sletta H et al. Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics. *Antimicrob Agents Chemother* 2012; **56**: 5134–41. <https://doi.org/10.1128/AAC.00525-12>
- 31** Georgiou M, Muñoz R, Román F et al. Ciprofloxacin-resistant *Haemophilus influenzae* strains possess mutations in analogous positions of GyrA and ParC. *Antimicrob Agents Chemother* 1996; **40**: 1741–4. <https://doi.org/10.1128/AAC.40.7.1741>
- 32** Dawe H, Berger E, Sihlbom C et al. D-methionine interferes with nontypeable *Haemophilus influenzae* peptidoglycan synthesis during growth and biofilm formation. *Microbiology (Reading)* 2017; **163**: 1093–104. <https://doi.org/10.1099/mic.0.000491>
- 33** Marti S, Puig C, Merlos A et al. Bacterial lysis through interference with peptidoglycan synthesis increases biofilm formation by nontypeable *Haemophilus influenzae*. *mSphere* 2017; **2**: e00329–16. <https://doi.org/10.1128/mSphere.00329-16>
- 34** Harrison A, Hardison RL, Wallace RM et al. Reprioritization of biofilm metabolism is associated with nutrient adaptation and long-term survival of *Haemophilus influenzae*. *NPJ Biofilms Microbiomes* 2019; **5**: 33. <https://doi.org/10.1038/s41522-019-0105-6>
- 35** Brockman KL, Azzari PN, Branstool MT et al. Epigenetic regulation alters biofilm architecture and composition in multiple clinical isolates of nontypeable *Haemophilus influenzae*. *mBio* 2018; **9**: e01682–18. <https://doi.org/10.1128/mBio.01682-18>
- 36** Devaraj A, Buzzo J, Rocco CJ et al. The DNABII family of proteins is comprised of the only nucleoid associated proteins required for nontypeable *Haemophilus influenzae* biofilm structure. *Microbiologyopen* 2018; **7**: e00563. <https://doi.org/10.1002/mbo3.563>
- 37** Vermeë Q, Cohen R, Hays C et al. Biofilm production by *Haemophilus influenzae* and *Streptococcus pneumoniae* isolated from the nasopharynx of children with acute otitis media. *BMC Infect Dis* 2019; **19**: 44. <https://doi.org/10.1186/s12879-018-3657-9>
- 38** Brown JR, Jurcisek J, Lakhani V et al. In silico modeling of biofilm formation by nontypeable *Haemophilus influenzae* in vivo. *mSphere* 2019; **4**: e00254–19. <https://doi.org/10.1128/mSphere.00254-19>
- 39** Thieme L, Hartung A, Tramm K et al. MBEC versus MBIC: the lack of differentiation between biofilm reducing and inhibitory effects as a current problem in biofilm methodology. *Biol Proced Online* 2019; **21**: 18. <https://doi.org/10.1186/s12575-019-0106-0>
- 40** Macia MD, Rojo-Molinero E, Oliver A. Antimicrobial susceptibility testing in biofilm-growing bacteria. *Clin Microbiol Infect* 2014; **20**: 981–90. <https://doi.org/10.1111/1469-0691.12651>
- 41** EUCAST. Amoxicillin: Rationale for the clinical breakpoints, version 1.0. 2010. [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Rationale\\_documents/Amoxicillin\\_rationale\\_Nov2010\\_v\\_1.0.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Amoxicillin_rationale_Nov2010_v_1.0.pdf).
- 42** EUCAST. Ciprofloxacin: Rationale for the clinical breakpoints, version 1.9. 2007. [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Rationale\\_documents/Ciprofloxacin\\_Rationale\\_Document\\_2.0\\_20210101.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Ciprofloxacin_Rationale_Document_2.0_20210101.pdf).
- 43** EMA. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. 2016. [https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-pharmacokinetics-pharmacodynamics-development-antimicrobial-medicinal-products\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-pharmacokinetics-pharmacodynamics-development-antimicrobial-medicinal-products_en.pdf).
- 44** Doern CD. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. *J Clin Microbiol* 2014; **52**: 4124–8. <https://doi.org/10.1128/JCM.01121-14>

- 45** Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. *Pharmacol Rev* 1995; **47**: 331–85.
- 46** Prichard MN, Shipman C Jr. A three-dimensional model to analyze drug-drug interactions. *Antiviral Res* 1990; **14**: 181–205. [https://doi.org/10.1016/0166-3542\(90\)90001-N](https://doi.org/10.1016/0166-3542(90)90001-N)
- 47** Hoiby N, Bjarnsholt T, Moser C et al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. *Clin Microbiol Infect* 2015; **21** Suppl 1: S1–25. <https://doi.org/10.1016/j.cmi.2014.10.024>
- 48** Ciofu O, Moser C, Jensen PO et al. Tolerance and resistance of microbial biofilms. *Nat Rev Microbiol* 2022; **20**: 621–35. <https://doi.org/10.1038/s41579-022-00682-4>
- 49** Kosikowska U, Andrzejczuk S, Plech T et al. Inhibitory effect of 1,2,4-triazole-ciprofloxacin hybrids on *Haemophilus parainfluenzae* and *Haemophilus influenzae* biofilm formation in vitro under stationary conditions. *Res Microbiol* 2016; **167**: 647–54. <https://doi.org/10.1016/j.resmic.2016.05.009>
- 50** Odds FC. Synergy, antagonism, and what the checkerboard puts between them. *J Antimicrob Chemother* 2003; **52**: 1. <https://doi.org/10.1093/jac/dkg301>